Recently developed drugs to fight sepsis, such as toll-like receptor 4 antagonists [8] and tumor necrosis factor-α (TNF-α) antibodies [9], have also failed to decrease mortality or provide clinical benefit in large phase III studies, and thus there remains a need to develop better treatment strategies. The gene discussed is TNF; the disease is Sepsis.